0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Restoration of the Prolactin Response to Sulpiride by Metergoline Administration in Hyperprolactinemic Patients

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although metergoline (MCE) inhibits prolactin (Prl) secretion in normal and hyperprolactinemic subjects similarly to dopamine (DA) and DA agonists, several data suggest that it acts through a different mechanism, probably as a serotonin antagonist. To further evaluate its Prl-lowering effect, paired sulpiride (Sulp) tests (100 mg i.m.) were performed before and after acute MCE administration (4 mg by mouth 120 min before Sulp) in 10 normal women, while 30 hyperprolactinemic women with pituitary microadenoma and no Prl response to Sulp were studied before and after acute or chronic treatment with either MCE (8–12 mg/day for 1-3 months) or bromocriptine (CB-154) (2.5 mg 300 min before Sulp, or 5 mg/day for 1-2 months), or during DA infusion (5 μg/kg/min for 180 min, Sulp being injected at 120 min). MCE did not alter the Sulp-stimulated Prl release in normal subjects and induced, both after acute and chronic administration, a clear Prl response to Sulp in hyperprolactinemic patients, which did not differ from that occurring in normals. During DA infusion, Sulp induced a marked increase in serum Prl levels, as previously reported in hyperprolactinemic patients without evidence of pituitary tumor; this increase was significantly higher than that observed in normals and in MCE-treated hyperprolactinemic subjects. No Prl response to Sulp occurred in CB-154-treated patients. Basal Prl levels were significantly lowered by all treatments. Although the similarity of effects of MCE and DA on Sulp-induced Prl release might suggest that MCE acts by stimulation of DA receptors, this hypothesis is not supported by pharmacological nor by in vitro and in vivo endocrinological studies; such an action might perhaps be exerted by the drug indirectly via serotoninergic blockade or through hypothetical metabolites. Alternatively, MCE might induce a Prl increase after Sulp in hyperprolactinemic patients by restoring the response of the normal lactotropes, usually suppressed by a central dopaminergic

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1979
          1979
          26 March 2008
          : 29
          : 5
          : 338-345
          Affiliations
          2nd Department of Medicine, Fatebenefratelli Hospital; Endocrine Unit, 2nd Medical Clinic, and Section of Endocrinology, Department of Obstetrics and Gynecology, University of Milan, Milan
          Article
          122942 Neuroendocrinology 1979;29:338–345
          10.1159/000122942
          503288
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Original Paper

          Comments

          Comment on this article